Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

consumer marketing

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

- PMLiVE

Aduro pancreatic cancer vaccine trial disappoints

Immunotherapy combination fails to improve overall survival over existing treatments

A frugal future

Novartis, GSK and AZ show that the demand for value is shaping our industry

dengue fever mosquito

Malaria vaccine is first to provide ‘sustained protection’

Latest trial shows immunological response lasts for at least a year

UK flag

UK biopharma says Brexit would be “bad for business”

Over 90 industry leaders sign letter supporting the Remain campaign

- PMLiVE

Respiratory return helps GSK to solid first quarter

Seretide decline offset by gains for new-generation products Anoro, Breo and Nucala

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

- PMLiVE

Stepping up to payer-driven market access

Giving the industry an opportunity to secure payers’ endorsements of its products by clearly illustrating product value

- PMLiVE

GSK’s morality gene

The firm is mutating in important ways - we should watch carefully

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links